"10.1371_journal.pmed.1001189","plos medicine","2012-03-20T00:00:00Z","Erick H Turner; Daniel Knoepflmacher; Lee Shapley","Department of Psychiatry, Oregon Health & Science University, Portland, Oregon, United States of America; Department of Pharmacology, Oregon Health & Science University, Portland, Oregon, United States of America; Center for Ethics in Health Care, Oregon Health & Science University, Portland, Oregon, United States of America; Behavioral Health and Neurosciences Division, Portland Veterans Affairs Medical Center, Portland, Oregon, United States of America; School of Medicine, Oregon Health & Science University, Portland, Oregon, United States of America","Conceived and designed the experiments: ET. Performed the experiments: ET DK LS. Analyzed the data: ET. Contributed reagents/materials/analysis tools: ET. Wrote the first draft: ET. Wrote the paper: ET DK LS. ICMJE criteria for authorship read and met: ET DK LS. Agree with the manuscripts results and conclusions: ET DK LS.","From 1998 to 2001, ET served as a medical reviewer at the US Food and Drug Administration (FDA). Subsequently, but ending in 2005, ET provided outside consulting to Bristol-Myers Squibb, Eli Lilly, and GlaxoSmithKline. From 2004 to 2005, ET was on the speakers bureaus of Eli Lilly, AstraZeneca, and Bristol-Myers Squibb. LS is Scorecard Director for the AMSA Pharmfree Scorecard, and a fourth year medical student at Oregon Health & Science University (OHSU). DK is also a fourth year medical student at OHSU and has no competing interests to report.","2012","03","Erick H Turner","EHT",3,FALSE,1,3,1,1,TRUE,TRUE,FALSE,0,NA,FALSE
